AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

LON:SKINIntegumen Share Price, Forecast & News

GBX 1.82
-0.08 (-4.20 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
1.76
Now: GBX 1.83
1.90
50-Day Range
0.93
MA: GBX 1.56
2
52-Week Range
0.01
Now: GBX 1.83
2.10
Volume6.99 million shs
Average Volume41,864 shs
Market Capitalization£19.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Integumen Plc develops technologies for skin and health care, personal-hygiene, pharmaceutical, and cosmetic industries in the United Kingdom and Ireland. The company offers Labskin AI, a cloud-based eco-system, which validates skincare products and ingredients. It also provides a range of men's skincare products under the STOER brand. Integumen Plc was incorporated in 2016 and is based in Dalkey, Ireland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars


Industry, Sector and Symbol

Industry Household & Personal Products
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+353-1-5373269

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£567,000.00
Cash FlowGBX 0.10 per share
Book ValueGBX 0.50 per share

Profitability

Miscellaneous

Employees11
Outstanding Shares1,072,419,968
Market Cap£19.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SKIN News and Ratings via Email

Sign-up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter.

Integumen (LON:SKIN) Frequently Asked Questions

How has Integumen's stock been impacted by COVID-19 (Coronavirus)?

Integumen's stock was trading at GBX 1.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SKIN stock has increased by 55.3% and is now trading at GBX 1.83. View which stocks have been most impacted by Coronavirus.

Has Integumen been receiving favorable news coverage?

Press coverage about SKIN stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Integumen earned a news impact score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutIntegumen.

Who are some of Integumen's key competitors?

What other stocks do shareholders of Integumen own?

Who are Integumen's key executives?

Integumen's management team includes the following people:
  • Mr. Gerard James Brandon, CEO & Director (Age 58)
  • Mr. Camillus Gerard Glover, CFO, Director & Company Sec. (Age 58)
  • Mr. Fionán Murray, COO & Director (Age 54)
  • Mr. James O'Sullivan, Chief Technology Officer
  • Mr. Colin O'Sullivan, Chief Information Officer

What is Integumen's stock symbol?

Integumen trades on the London Stock Exchange (LON) under the ticker symbol "SKIN."

How do I buy shares of Integumen?

Shares of SKIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Integumen's stock price today?

One share of SKIN stock can currently be purchased for approximately GBX 1.83.

How big of a company is Integumen?

Integumen has a market capitalization of £19.57 million and generates £567,000.00 in revenue each year. Integumen employs 11 workers across the globe.

What is Integumen's official website?

The official website for Integumen is www.integumen.co.uk.

How can I contact Integumen?

Integumen's mailing address is Dalkey, 19 Railway Road, DUBLIN, YO41 1LZ, Ireland. The company can be reached via phone at +353-1-5373269.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.